Overview

Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease

Status:
Terminated
Trial end date:
2020-05-21
Target enrollment:
Participant gender:
Summary
The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).
Phase:
Phase 1
Details
Lead Sponsor:
Alpine Immune Sciences, Inc.